Wisp, the largest women’s telehealth company in the U.S., today announced the acquisition of TBD Health, a national sexual health platform and one of the nat...

Wisp acquires sexual health platform TBD Health, expands into hybrid and enterprise care. Wisp, a US-based women's telehealth company, has acquired TBD Health, a sexual health platform operating across all 50 states. The deal terms were not disclosed. This marks Wisp's first acquisition and expands the company beyond direct-to-consumer care into enterprise and hybrid care models. TBD Health operates a sexual health and diagnostics platform offering STI and HIV testing, TelePrEP services, and virtual clinical support. The company has partnerships with Mount Sinai Health System, San Francisco AIDS Foundation, and Planned Parenthood Direct. "This acquisition reflects where healthcare is going and where women have been left behind," said Monica Cepak, CEO of Wisp. "TBD Health brings the infrastructure and partnerships that allow us to move into hybrid and enterprise care quickly, while staying true to Wisp's patient-first approach. Together, we are making preventative care more accessible especially to women and integrating them into proven care models." The acquisition addresses gaps in PrEP access for women. While women account for 19% of new HIV diagnoses in the United States, according to the company, most prevention models have historically been designed and marketed for men. Of the 2.4 million people eligible for PrEP treatment, only approximately 25% are currently enrolled. "By joining forces with Wisp, we can provide partners with a turnkey solution for PrEP along with sexual health diagnostics and care that integrates seamlessly into their existing workflows, ensuring no patient falls through the cracks," said Daphne Chen, co-founder of TBD Health. Wisp reports serving 1.8 million patients across the United States. The company is majority-owned by WELL Health Technologies Corp. TBD Health was co-founded by Stephanie Estey, Daphne Chen, and Sherwin Lu.

What You Should Know:–  Wisp, the largest U.S. telehealth company focused exclusively on women’s sexual and reproductive health, has launched its new diagnostics vertical, significantly expanding its service offerings.–  With over 1.5 million patients across all 50 states, Wisp is now providing convenient, affordable at-home testing for common sexually transmitted infections (STIs), coupled with integrated follow-up care within its existing virtual ecosystem.Wisp Launches Nationwide At-Home STI Testing to Expand Access to Women’s Diagnostic CareWisp is the largest pure-play women’s telehealth provider in the United States, delivering discreet, evidence-based treatments and a first-to-market product line across sexual and reproductive health. With services spanning all 50 states, Wisp continues to establish itself as a leading, all-in-one platform for women’s health.The new Wisp At-Home Testing Follow-Up Care service allows patients to:·       Collect swab and urine samples from home·       Ship samples to a CLIA/CAP-accredited lab using a prepaid label·       Receive accurate results within 3–5 business days·       Access discreet, evidence-based follow-up care through Wisp’s clinical teamThis launch addresses rising barriers in healthcare access, including nationwide provider shortages and stigma around STI testing. It also eliminates the previous need for third-party referrals by keeping the entire diagnostic and care process within Wisp’s system.Initial offerings include:·       Common STI Panel: Tests for Chlamydia, Gonorrhea, and Trichomoniasis·       3-Site Panel: Detects Chlamydia and Gonorrhea from three anatomical sites·       M-Gen Panel: Screens for Mycoplasma Genitalium (Mgen)Future plans include additional testing options in upcoming quarters, including hormonal health diagnostics and in-home blood draw services to bolster the fertility and menopause verticals.Survey data from Wisp shows that:·       62% of users express interest in STI testing·       STI, STD, and Herpes-related queries are up 40% year-over-year·       STIs such as Chlamydia, Gonorrhea, and Trichomoniasis disproportionately affect women under 25According to Wisp CEO Monica Cepak, integrating diagnostics into the platform was a natural evolution, aligning with the company’s mission to deliver 360-degree care through affordability, discretion, and convenience. All test kits are priced at the lowest market rates and include free virtual consultations for follow-up.Dr. Jillian LoPiano, MD, MPH, FACOG, emphasized the clinical impact of discreet, reliable diagnostics, noting their potential to destigmatize sexual health and empower women to proactively manage their care